Moderator,
Please let me start by saying that i currently take and have in the past taken Lamictal and Lithium. I have tried both of these as well as almost every drug available in the market if the pdocs prescribe to me as well as the drugs to counteract the side effects of the psych drugs.
I choose hope with death to what I have become. That is my choice, but I have made it with all of the technical components to enable me to do that. Being educated about the chemicals that I have running through my body and brain, leaving chemical remnants, may be the last bit of control I have left in my life. I believe that everyone deserves that last bit... don't you?
I believe in understanding what I put into my body - food, beverage, vitamins/ minerals, and medicines (chemicals). Only pdocs and you are able to understand what goes into your body. Wouldn't you want to know if the mushrooms that you eat are toxic or can make you hallucinate or just plain taste good??? I want to know the same about these meds.
Please look on the FDA website (Food and Drug Administration - government appoving body for available drugs in the US) -
www.fda.gov It details everything that you should know all US approved drugs.
http://www.nimh.nih.gov/ (National Institute of Mental Heath - contains studies completed, being explored, or about to happen as well as papers on drugs anaylsis - Is a government body subsidiary of NIH - The National Institite of Health
http://www.nih.gov/.
Although, I leave open for others to research their own meds using RELIABLE sources of information, I will address the Lamictal issue specifically - since you repeatedly, obviously without all of GSK disclosed data about the potential lethal, physical deformation, and permanent disabling risks, I have included a snippet from GSK's (Glaxo Smith-Kline Pharmacuetical Corp. :
www.gsk.com) released Lamictal documentation (on their web site for Lamictal:
http://www.lamictal.com/bipolar/patients/s...g_lamictal.html ) You are actually correct in that it is not necessarily a restart of the drug for the lethal issues to occur in people using lamictal. I ask that you read the following excerpt from the documentation noted above "
Complete Prescribing Information for LAMICTAL" The immediately preceeding link is a pdf file containing the full document from which the following was extracted without modification.
PRESCRIBING INFORMATION
LAMICTAL®
(lamotrigine)
Tablets
LAMICTAL®
(lamotrigine)
Chewable Dispersible Tablets
SERIOUS RASHES REQUIRING HOSPITALIZATION AND DISCONTINUATION OF TREATMENT HAVE BEEN REPORTED IN ASSOCIATION WITH THE USE OF LAMICTAL. THE INCIDENCE OF THESE RASHES, WHICH HAVE INCLUDED STEVENS-JOHNSON SYNDROME, IS APPROXIMATELY 0.8% (8 PER 1,000) IN PEDIATRIC PATIENTS (AGE <16 YEARS) RECEIVING LAMICTAL AS ADJUNCTIVE THERAPY FOR EPILEPSY AND 0.3% (3 PER 1,000) IN ADULTS ON ADJUNCTIVE THERAPY FOR EPILEPSY. IN CLINICAL TRIALS OF BIPOLAR AND OTHER MOOD DISORDERS, THE RATE OF SERIOUS RASH WAS 0.08% (0.8 PER 1,000) IN ADULT PATIENTS RECEIVING LAMICTAL AS INITIAL MONOTHERAPY AND 0.13% (1.3 PER 1,000) IN ADULT PATIENTS RECEIVING LAMICTAL AS ADJUNCTIVE THERAPY. IN A PROSPECTIVELY FOLLOWED COHORT OF 1,983 PEDIATRIC PATIENTS WITH EPILEPSY TAKING ADJUNCTIVE LAMICTAL, THERE WAS 1 RASH-RELATED DEATH. IN WORLDWIDE POSTMARKETING EXPERIENCE, RARE CASES OF TOXIC EPIDERMAL NECROLYSIS AND/OR RASH-RELATED DEATH HAVE BEEN REPORTED IN ADULT AND PEDIATRIC PATIENTS, BUT THEIR NUMBERS ARE TOO FEW TO PERMIT A PRECISE ESTIMATE OF THE RATE.
OTHER THAN AGE, THERE ARE AS YET NO FACTORS IDENTIFIED THAT ARE KNOWN TO PREDICT THE RISK OF OCCURRENCE OR THE SEVERITY OF RASH ASSOCIATED WITH LAMICTAL. THERE ARE SUGGESTIONS, YET TO BE PROVEN, THAT THE RISK OF RASH MAY ALSO BE INCREASED BY (1) COADMINISTRATION OF LAMICTAL WITH VALPROATE (INCLUDES VALPROIC ACID AND DIVALPROEX SODIUM), (2) EXCEEDING THE RECOMMENDED INITIAL DOSE OF LAMICTAL, OR (3) EXCEEDING THE RECOMMENDED DOSE ESCALATION FOR LAMICTAL. HOWEVER, CASES HAVE BEEN REPORTED IN THE ABSENCE OF THESE FACTORS.
NEARLY ALL CASES OF LIFE-THREATENING RASHES ASSOCIATED WITH LAMICTAL HAVE OCCURRED WITHIN 2 TO 8 WEEKS OF TREATMENT INITIATION. HOWEVER, ISOLATED CASES HAVE BEEN REPORTED AFTER PROLONGED TREATMENT (E.G., 6 MONTHS). ACCORDINGLY, DURATION OF
1
THERAPY CANNOT BE RELIED UPON AS A MEANS TO PREDICT THE POTENTIAL RISK HERALDED BY THE FIRST APPEARANCE OF A RASH.
ALTHOUGH BENIGN RASHES ALSO OCCUR WITH LAMICTAL, IT IS NOT POSSIBLE TO PREDICT RELIABLY WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE THREATENING. ACCORDINGLY, LAMICTAL SHOULD ORDINARILY BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. DISCONTINUATION OF TREATMENT MAY NOT PREVENT A RASH FROM BECOMING LIFE THREATENING OR PERMANENTLY DISABLING OR DISFIGURING.